$PHIO
Phio Pharmaceuticals Corp Stock $phio

$phio Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000119312517253552 Filed on August 10, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$0.00	$0.00	$9.000K
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$990.0K	$1.100M	$890.0K
YoY Change	32.0%	23.6%	11.25%
% of Gross Profit
Research & Development	$1.490M	$1.329M	$1.339M
YoY Change	1.78%	-0.75%	-1.62%
% of Gross Profit
Depreciation & Amortization	$20.00K	$20.00K	$20.00K
YoY Change	100.0%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$2.476M	$2.514M	$2.224M
YoY Change	11.73%	13.04%	2.73%
Operating Profit	-$2.476M	-$2.514M	-$2.215M
YoY Change	11.73%	13.5%	2.31%
Interest Expense	$0.00	$0.00	$4.000K
YoY Change	-100.0%	-100.0%	300.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$3.000K
YoY Change	-100.0%	-100.0%	-400.0%
Pretax Income	-$2.480M	-$2.510M	-$2.210M
YoY Change	12.22%	13.57%	1.84%
Income Tax
% Of Pretax Income
Net Earnings	-$2.476M	-$2.514M	-$2.212M
YoY Change	11.93%	13.65%	2.12%
Net Earnings / Revenue			-24577.78%
Basic Earnings Per Share
Diluted Earnings Per Share	-$62.00M	-$62.75M	-$221.0M
COMMON SHARES
Basic Shares Outstanding	23.25M shares	22.13M shares	6.535M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.420M	$7.700M	$5.830M
YoY Change	23.74%	32.08%	-58.33%
Cash & Equivalents	$5.416M	$7.702M	$3.832M
Short-Term Investments			$2.000M
Other Short-Term Assets	$320.0K	$390.0K	$530.0K
YoY Change	-13.51%	-26.42%	-31.17%
Inventory
Prepaid Expenses	$271.0K	$337.0K	$477.0K
Receivables
Other Receivables
Total Short-Term Assets	$5.737M	$8.089M	$6.359M
YoY Change	20.78%	27.21%	-56.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$269.0K	$275.0K	$135.0K
YoY Change	116.94%	103.7%	-25.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$27.00K	$27.00K	$27.00K
YoY Change	0.0%	0.0%	50.0%
Total Long-Term Assets	$296.0K	$302.0K	$162.0K
YoY Change	96.03%	86.42%	-18.59%
TOTAL ASSETS
Total Short-Term Assets	$5.737M	$8.089M	$6.359M
Total Long-Term Assets	$296.0K	$302.0K	$162.0K
Total Assets	$6.033M	$8.391M	$6.521M
YoY Change	23.1%	28.68%	-56.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$702.0K	$741.0K	$297.0K
YoY Change	53.61%	149.49%	-53.23%
Accrued Expenses	$1.901M	$1.713M	$1.256M
YoY Change	35.01%	36.39%	5.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.603M	$2.454M	$1.553M
YoY Change	39.57%	58.02%	-14.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.603M	$2.454M	$1.553M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.600M	$2.450M	$1.550M
YoY Change	39.04%	58.06%	-14.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$76.55M	-$74.07M	-$61.55M
YoY Change	20.06%	20.35%	18.38%
Common Stock	$2.000K	$2.000K	$1.000K
YoY Change	100.0%	100.0%	-83.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.430M	$5.937M	$4.968M
YoY Change
Total Liabilities & Shareholders Equity	$6.033M	$8.391M	$6.521M
YoY Change	23.1%	28.68%	-56.39%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$2.476M	-$2.514M	-$2.212M
YoY Change	11.93%	13.65%	2.12%
Depreciation, Depletion And Amortization	$20.00K	$20.00K	$20.00K
YoY Change	100.0%	0.0%	0.0%
Cash From Operating Activities	-$2.190M	-$2.320M	-$1.860M
YoY Change	36.88%	24.73%	3.33%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$190.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$1.500M
YoY Change		-100.0%	-118.75%
Cash From Investing Activities	-$10.00K	-$190.0K	$1.500M
YoY Change		-112.67%	-118.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-70.00K		0.000
YoY Change	-146.67%		-100.0%
NET CHANGE
Cash From Operating Activities	-2.190M	-2.320M	-1.860M
Cash From Investing Activities	-10.00K	-190.0K	1.500M
Cash From Financing Activities	-70.00K		0.000
Net Change In Cash	-2.270M	-2.510M	-360.0K
YoY Change	56.55%	597.22%	-38.98%
FREE CASH FLOW
Cash From Operating Activities	-$2.190M	-$2.320M	-$1.860M
Capital Expenditures	-$10.00K	-$190.0K
Free Cash Flow	-$2.180M	-$2.130M
YoY Change	36.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23247338	shares
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3832000
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	50000
CY2016Q2	rxii	Cash And Cash Equivalents And Restricted Cash At Carrying Value CashAndCashEquivalentsAndRestrictedCashAtCarryingValue	3882000
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1713000
CY2017Q2	us-gaap	Assets Current AssetsCurrent	8089000
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80008000
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	741000
CY2017Q2	us-gaap	Assets Assets	8391000
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7702000
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23246218	shares
CY2017Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14077779	shares
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23246218	shares
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	2000
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8391000
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2454000
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27000
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	337000
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	275000
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	50000
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50000
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-74073000
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	328317	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	28.15
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	677451	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.43
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	5937000
CY2017Q2	rxii	Cash And Cash Equivalents And Restricted Cash At Carrying Value CashAndCashEquivalentsAndRestrictedCashAtCarryingValue	7752000
CY2015Q4	rxii	Cash And Cash Equivalents And Restricted Cash At Carrying Value CashAndCashEquivalentsAndRestrictedCashAtCarryingValue	5167000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1625000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	13106000
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	73428000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	917000
CY2016Q4	us-gaap	Assets Assets	13397000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12906000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13003179	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13003179	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13397000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2542000
CY2016Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	150000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27000
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	150000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	50000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66099000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	374446	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.29
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	10855000
CY2016Q4	rxii	Cash And Cash Equivalents And Restricted Cash At Carrying Value CashAndCashEquivalentsAndRestrictedCashAtCarryingValue	12956000
CY2017Q1	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	2750371	shares
CY2017Q1	rxii	Holdback Percentage HoldbackPercentage	0.03	pure
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14755230	shares
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2223000
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	100000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Entity Registrant Name EntityRegistrantName	RXi Pharmaceuticals Corp
	dei	Entity Central Index Key EntityCentralIndexKey	0001533040
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	2824000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	88000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-378000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	187000
	us-gaap	Maturities Of Time Deposits Description MaturitiesOfTimeDepositsDescription	Three months or less
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Nature of Operations</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> RXi Pharmaceuticals Corporation (“<b>RXi</b>,” “<b>we</b>,” “<b>our</b>” or the “<b>Company</b>”) is a clinical-stage company developing innovative therapeutics based on our proprietary self-delivering RNAi <font style="white-space:nowrap">(sd-rxRNA</font><sup style="font-size:85%; vertical-align:top">®</sup>) platform and Samcyprone™ which address significant unmet medical needs. We have a pipeline of discovery, preclinical and clinical product candidates in the areas of dermatology, ophthalmology and cell-based cancer immunotherapy. The Company’s clinical development programs include <font style="white-space:nowrap">RXI-109,</font> an <font style="white-space:nowrap">sd-rxRNA</font> for the treatment of dermal and ocular scarring, and Samcyprone™, a topical immunomodulator, for the treatment of warts. The Company’s pipeline, coupled with our extensive patent portfolio, provides for product development and business development opportunities across a broad spectrum of therapeutic areas.</p> </div>
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-88000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5116000
	us-gaap	Operating Expenses OperatingExpenses	7974000
	us-gaap	Net Income Loss NetIncomeLoss	-7974000
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	5000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7974000
	us-gaap	Notes Reduction NotesReduction	150000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	188000
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	3075000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2676000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	233000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.2301	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	25379	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	26.28
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8299	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0173	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.49
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.69
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.8463	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	22000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0249	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	328384	shares
	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	2750371	shares
	dei	Trading Symbol TradingSymbol	RXII
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21484772	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Uses of Estimates in Preparation of Financial Statements</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> </div>
	rxii	Cash And Cash Equivalents And Restricted Cash Period Increase Decrease CashAndCashEquivalentsAndRestrictedCashPeriodIncreaseDecrease	-5204000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2946935	shares
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1835000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	150000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-866000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	166000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	11000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3500000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4785000
	us-gaap	Operating Expenses OperatingExpenses	4479000
	us-gaap	Net Income Loss NetIncomeLoss	-4443000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4460000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	2000000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	5500000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2644000
	us-gaap	Revenues Revenues	19000
	us-gaap	Share Based Compensation ShareBasedCompensation	521000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1670	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7942	pure
CY2016Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	4000
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	2224000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0202	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6534846	shares
	rxii	Value Of Nonmarketable Equity Securities Recognized As Revenue ValueOfNonmarketableEquitySecuritiesRecognizedAsRevenue	9000
	rxii	Cash And Cash Equivalents And Restricted Cash Period Increase Decrease CashAndCashEquivalentsAndRestrictedCashPeriodIncreaseDecrease	-1285000
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0118	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.15
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.8864	pure
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	885000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-2212000
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2215000
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3000
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1339000
CY2016Q2	us-gaap	Revenues Revenues	9000
CY2016Q2	us-gaap	Share Based Compensation ShareBasedCompensation	227000
CY2016Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	0	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6534846	shares
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1100000
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	2514000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-2514000
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2514000
CY2017Q2	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	85000
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1329000
CY2017Q2	us-gaap	Share Based Compensation ShareBasedCompensation	119000
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1518	pure
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8299	pure
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0173	pure
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.47
CY2017Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	0	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.8551	pure
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	22000
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0225	pure
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22388360	shares

Files In Submission

Name	View Source	Status
0001193125-17-253552-index-headers.html	Edgar Link	pending
0001193125-17-253552-index.html	Edgar Link	pending
0001193125-17-253552.txt	Edgar Link	pending
0001193125-17-253552-xbrl.zip	Edgar Link	pending
d313418d10q.htm	Edgar Link	pending
d313418dex311.htm	Edgar Link	pending
d313418dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rxii-20170630.xml	Edgar Link	completed
rxii-20170630.xsd	Edgar Link	pending
rxii-20170630_cal.xml	Edgar Link	unprocessable
rxii-20170630_def.xml	Edgar Link	unprocessable
rxii-20170630_lab.xml	Edgar Link	unprocessable
rxii-20170630_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PHIO
Phio Pharmaceuticals Corp Stock $phio

2017 Q3 Form 10-Q Financial Statement

#000119312517253552 Filed on August 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHIO Phio Pharmaceuticals Corp Stock $phio

2017 Q3 Form 10-Q Financial Statement

#000119312517253552 Filed on August 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHIO
Phio Pharmaceuticals Corp Stock $phio